Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit
Milan, 20133, Italy
NCT Number: NCT04968093
Chronic Migraine (CM) and High Frequency Episodic Migraine (HFEM) without Aura affect adolescents' lives in terms of reduced health, reduced ability to perform daily chores and reduced quality of life. The use of pharmacological prophylaxis in these patients warrants caution, whereas the use of behavioral treatments is gaining support in literature.
The main aim of MINDKIDS trial is to test the effect of a seven weekly group sessions of guided mindfulness-based meditation program on 12-month headache frequency reduction, medications intake, disability, anxiety, depression, catastrophizing, and caregivers' burden.
This is a single-arm study. All patients will participate to seven weekly guided sessions (60 minutes each) of guided mindfulness meditation, which is aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. The intervention's main topics are: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts. Each session is conducted by a neurologist and a psychologist expert in mindfulness practice. During the sessions, patients are asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations.
Patients were educated to promote a healthy lifestyle: regular physical activity, avoiding skipping meals, hydration, maintain a regular sleep/wake pattern at least 7-8 hours per night.
Looking for future studies?
Notify Me12 year–18 year
All sexes
Interventional
Not applicable
Milan, 20133, Italy
Background and significance Adolescents with Chronic Migraine (CM) and High Frequency Episodic Migraine (HFEM) without Aura, characterized by 15+ and 9-14 days with headache respectively, pose a relevant burden on adolescents' health, quality of life, as well as on their ability to perform school and leisure time activity. In addition to this, tackling such health conditions in adolescence might be of great importance to reduce the likelihood of a transition to adulthood with CM and medication overuse headache.
In this category of patients, it is suggested to avoid prescribing pharmacological prophylaxis, in favour of non-pharmacological approaches, such as nutraceuticals or behavioural techniques.
Behavioural approaches are considered helpful for younger patients with HFEM and CM to manage pain and to reduce the number of analgesics and the use preventive medications. Mindfulness, in particular, has been applied in several clinical experiences in adults with pain and migraine with encouraging results, with long term benefit similar to that obtained from pharmacological prophylaxis. The clinical use of mindfulness in adolescents is limited to few experiences, however some results in this group of patients are encouraging. A non-randomized pilot study demonstrated acceptability and feasibility of a mindfulness-based treatment for adolescents with recurrent headaches (1). Another study demonstrated how mindfulness was able to reduce depression in children and adolescents suffering from migraine associated with depression (2). A third small pilot study (3) showed positive results with the use of mindfulness in young patients with headache.
Taken as a whole, these studies seem to point out that mindfulness-based protocol for adolescents with CM or HFEM are feasible and acceptable. What has to be better addressed is the effect of such a kind of treatment: available information, however, enable us to hypothesize that reduction in headache frequency from baseline over a 12-months period could be higher or equal to 50%.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
one of the two main diagnoses are to me met.
The clinical features are those of code 1.1 of the ICHD-3, with headache lasting 2-72 hours (which is specific to populations aged <18) and with frequency 8-14 days/month for >3 months.
Exclusion criteria
Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.
Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts.
Time frame: 6 and 12 months
Time frame: 12 months
Time frame: 6 and 12 months
Time frame: 6 and 12 months
The PedMIDAS is composed of six items addressing the missed and partially missed school-days, missed and partially missed days for homework activities, missed and partially missed days for leisure activities. The total PedMIDAS score is determined by the sum of items' scores and four severity categories are established: 0-10 no or minimal disability; 11-30 light disability; 31-50 moderate disability; more than 50 high disability
Time frame: 6 and 12 months
The STAI-CH is composed by 20 items, rated on a 1-4 scale, which evaluate state anxiety (i.e. temporary feelings at the time of a perceived threat; 0=not at all - 4=very much) and 20 items evaluating trait anxiety (i.e. feelings of stress and worry experienced on a day to day basis; 0=almost never - 4=almost always). The score range is between 20 and 80: higher scores correspond to higher anxiety levels.
Time frame: 6 and 12 months
The CDI consists of 27 items evaluating different symptoms of depression, including mood disturbances, vegetative functions, social behaviour, ability to feel good sensations, self-esteem. The items investigate the influence of depressions in specific contests for young patients. Each item is scored on a 0-2 scale (0=no problem; 1= moderate problem; 2=serious problem) and the total score range is 0-54. A total score higher than 19 indicates risk of depression.
Time frame: 6 and 12 months
The PCS addresses the concept of catastrophizing as it relates to pain, i.e. an exaggerated negative mental set brought to bear during actual or anticipated painful experience. It is composed by three subscales each identifying specific dimensions: rumination, which refers to the constant thinking about pain; magnification, which refers to the exaggeration of pain and of its consequences; helplessness, which refers to the belief that there is no or limited possibility that pain may improve. This measure is composed of 13 items, each rated from 0 = "not at all" to 4 = "all the time," yielding total scores ranging from 0 to 52, with higher scores indicating higher tendencies to catastrophize and score values ≥ 30 indicating clinically significant levels of catastrophizing
Time frame: 6 and 12 months
The CBI consists of 24 items evaluated on a 0-4 scale (0=not at all - 4=very much) that describe emotional reactions and difficulties related to the caregiving activity. The items assess issues related to the time required for assistance, the perception of being cut off from other activities and possibilities, fatigue, the reduction of social activities and feelings towards the relative. The total score is linearly transformed on a 0-100 scale: higher scores indicate greater burden.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Other
Effect and Feasibility of a Mindfulness-based Treatment for Adolescents Aged 12-18 With Chronic Migraine and High Frequency Episodic Migraine Without Aura
Acronym: MINDKIDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06966037
Brain Diseases, Central Nervous System Diseases
Mersin, Turkey (Türkiye)
View Trial DetailsNCT06180577
Brain Diseases, Central Nervous System Diseases
Bridgewater, New Jersey, United States
View Trial DetailsNCT04537429
Brain Diseases, Central Nervous System Diseases
Stamford, Connecticut, United States
View Trial DetailsNCT03806595
Brain Diseases, Central Nervous System Diseases
Vancouver, British Columbia, Canada
View Trial Details